This will be a live, interactive online event in which investors are invited to ask the company questions in real-time. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors. (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite Bio’s Chief Scientific Officer, Nathan Mata will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference (dbVIC) on November 8. 06, 2023 (GLOBE NEWSWIRE) - Belite Bio, Inc.
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event
